Dr. Martens plc (LON:DOCS – Get Free Report) insider Giles Wilson bought 207 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were acquired at an average cost of GBX 73 ($0.92) per share, for a total transaction of £151.11 ($190.20).
Giles Wilson also recently made the following trade(s):
- On Monday, January 13th, Giles Wilson bought 222 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 68 ($0.86) per share, for a total transaction of £150.96 ($190.01).
Dr. Martens Trading Down 0.0 %
LON DOCS opened at GBX 72 ($0.91) on Friday. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The company has a market capitalization of £698.90 million, a price-to-earnings ratio of 10.21, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company’s 50-day simple moving average is GBX 72.34 and its two-hundred day simple moving average is GBX 65.63. Dr. Martens plc has a one year low of GBX 49.32 ($0.62) and a one year high of GBX 100 ($1.26).
Dr. Martens Cuts Dividend
The company also recently declared a dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Thursday, March 6th will be issued a GBX 0.85 ($0.01) dividend. This represents a dividend yield of 1.47%. The ex-dividend date of this dividend is Thursday, March 6th. Dr. Martens’s dividend payout ratio is currently 42.53%.
Dr. Martens Company Profile
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Recommended Stories
- Five stocks we like better than Dr. Martens
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
- Top Biotech Stocks: Exploring Innovation Opportunities
- Up 50% in January, Twilio’s Pullback Is the Time to Buy
- How to Invest in Small Cap Stocks
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.